Epidyolex

Product data

Locally preserved regulatory fields

Active ingredients

cannabidiol

Route

Not reported

Dosage form

Not reported

Marketing holder

Jazz Pharmaceuticals Ireland Limited

Catalog status

Authorised

Source-reported status

Authorised

Linked local records

Related local records

Substance links use source-reported active ingredients. Condition links come from registered study context and are not efficacy claims.

Source-reported use

Indications in regulatory records

Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.

Medicine identity matching

RxNorm candidates

RxNorm normalizes identity; FAERS supplies non-causal post-market signals.

Safety signals

Locally preserved FAERS reports

FAERS/AEMS reports are post-market signals. Counts do not establish causality or incidence and may contain duplicates or reporting bias.